Compare · NXGL vs WST
NXGL vs WST
Side-by-side comparison of NexGel Inc (NXGL) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NXGL and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $25.31B, about 5819.7x NXGL ($4.3M).
- Over the past year, NXGL is down 81.6% and WST is up 69.7% - WST leads by 151.3 points.
- WST has been more active in the news (5 items in the past 4 weeks vs 3 for NXGL).
- WST has more recent analyst coverage (18 ratings vs 1 for NXGL).
- Company
- NexGel Inc
- West Pharmaceutical Services Inc.
- Price
- $0.44+1.32%
- $358.18-1.11%
- Market cap
- $4.3M
- $25.31B
- 1M return
- -19.29%
- +8.72%
- 1Y return
- -81.61%
- +69.72%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 3
- 5
- Recent ratings
- 1
- 18
NexGel Inc
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest NXGL
- SEC Form 8-K filed by NexGel Inc
- SEC Form 8-K filed by NexGel Inc
- Chief Executive Officer Levy Adam R. sold $6,519 worth of shares (11,000 units at $0.59), decreasing direct ownership by 3% to 322,692 units (SEC Form 4)
- NexGel Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Executive Officer Levy Adam R. sold $1,841 worth of shares (3,000 units at $0.61), decreasing direct ownership by 0.89% to 333,692 units (SEC Form 4)
- Chief Executive Officer Levy Adam R. sold $3,422 worth of shares (6,000 units at $0.57), decreasing direct ownership by 2% to 336,692 units (SEC Form 4)
- SEC Form DEF 14A filed by NexGel Inc
- NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th
- Chief Executive Officer Levy Adam R. sold $1,172 worth of shares (2,000 units at $0.59), decreasing direct ownership by 0.58% to 342,692 units (SEC Form 4)
- Chief Executive Officer Levy Adam R. sold $7,834 worth of shares (13,000 units at $0.60), decreasing direct ownership by 4% to 344,692 units (SEC Form 4)
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits